The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice

Epilepsy and Behavior

Volumn 22, Issue 2, 2011, Pages 200-206

  Moezi, Leila ^a,b   Shafaroodi, Hamed ^c   Hojati, Abolfazl ^a   Dehpour, Ahmad R ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Agmatine; Melatonin; Melatonin receptors; Mice; Pentylenetetrazole; Seizure

Indexed keywords

AGMATINE; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN 3 RECEPTOR; MELATONIN RECEPTOR; PENTETRAZOLE; PRAZOSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MALE; MOUSE; NONHUMAN; SEIZURE THRESHOLD;

AGMATINE; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MELATONIN; MICE; PENTYLENETETRAZOLE; PRAZOSIN; RECEPTORS, MELATONIN; SEIZURES; TIME FACTORS; TRYPTAMINES;

EID: 80053384017     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.07.002     Document Type: Article

References (59)

1. Brzezinski A. Melatonin in humans. N Engl J Med 1997, 336:186-195.
2. Czeisler C.A. Commentary: evidence for melatonin as a circadian phase-shifting agent. J Biol Rhythms 1997, 12:618-623.
3. Acuna-Castroviejo D., Escames G., Macias M., et al. Cell protective role of melatonin in the brain. J Pineal Res 1995, 19:57-63.
4. Wan Q., Man H.Y., Liu F., et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci 1999, 2:401-403.
5. Golombek D.A., Pevet P., Cardinali D.P. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev 1996, 20:403-412.
6. Dawson D., Encel N. Melatonin and sleep in humans. J Pineal Res 1993, 15:1-12.
7. Albertson T.E., Peterson S.L., Stark L.G., Lakin M.L., Winters W.D. The anticonvulsant properties of melatonin on kindled seizures in rats. Neuropharmacology 1981, 20:61-66.
8. Mevissen M., Ebert U. Anticonvulsant effects of melatonin in amygdala-kindled rats. Neurosci Lett 1998, 257:13-16.
9. Borowicz K.K., Kaminski R., Gasior M., Kleinrok Z., Czuczwar S.J. Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol 1999, 9:185-190.
10. Champney T.H., Hanneman W.H., Legare M.E., Appel K. Acute and chronic effects of melatonin as an anticonvulsant in male gerbils. J Pineal Res 1996, 20:79-83.
11. Ray M., Mediratta P.K., Reeta K., Mahajan P., Sharma K.K. Receptor mechanisms involved in the anticonvulsant effect of melatonin in maximal electroshock seizures. Methods Find Exp Clin Pharmacol 2004, 26:177-181.
12. Bikjdaouene L., Escames G., Leon J., et al. Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures. J Pineal Res 2003, 35:54-60.
13. Rosenstein R.E., Chuluyan H.E., Diaz M.C., Cardinali D.P. GABA as a presumptive paracrine signal in the pineal gland: evidence on an intrapineal GABAergic system. Brain Res Bull 1990, 25:339-344.
14. Schapel G.J., Beran R.G., Kennaway D.L., McLoughney J., Matthews C.D. Melatonin response in active epilepsy. Epilepsia 1995, 36:75-78.
15. Molina-Carballo A., Munoz-Hoyos A., Rodriguez-Cabezas T., Acuna-Castroviejo D. Day-night variations in melatonin secretion by the pineal gland during febrile and epileptic convulsions in children. Psychiatry Res 1994, 52:273-283.
16. Molina-Carballo A., Munoz-Hoyos A., Reiter R.J., et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 1997, 23:97-105.
17. Elkhayat H.A., Hassanein S.M., Tomoum H.Y., Abd-Elhamid I.A., Asaad T., Elwakkad A.S. Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol 2010, 42:249-254.
18. Paprocka J., Dec R., Jamroz E., Marszal E. Melatonin and childhood refractory epilepsy: a pilot study. Med Sci Monit 2010, 16:CR389-CR396.
19. Raasch W., Schafer U., Chun J., Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 2001, 133:755-780.
20. Kolesnikov Y., Jain S., Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996, 296:17-22.
21. Yesilyurt O., Uzbay I.T. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 2001, 25:98-103.
22. Aricioglu-Kartal F., Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997, 61:1775-1781.
23. Morgan A.D., Campbell U.C., Fons R.D., Carroll M.E. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav 2002, 72:873-880.
24. Fairbanks C.A., Schreiber K.L., Brewer K.L., et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci U S A 2000, 97:10584-10589.
25. Gonzalez C., Regunathan S., Reis D.J., Estrada C. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharmacol 1996, 119:677-684.
26. Jurkiewicz N.H., Garcez do Carmo L., Hirata H., da Costa Santos W., Jurkiewicz A. Functional properties of agmatine in rat vas deferens. Eur J Pharmacol 1996, 307:299-304.
27. Demehri S., Homayoun H., Honar H., et al. Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 2003, 45:534-542.
28. Bence A.K., Worthen D.R., Stables J.P., Crooks P.A. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav 2003, 74:771-775.
29. Su R.B., Wei X.L., Zheng J.Q., Liu Y., Lu X.Q., Li J. Anticonvulsive effect of agmatine in mice. Pharmacol Biochem Behav 2004, 77:345-349.
30. Luszczki J.J., Czernecki R., Dudra-Jastrzebska M., Borowicz K.K., Czuczwar S.J. Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice. Pharmacol Rep 2009, 61:252-260.
31. Yahyavi-Firouz-Abadi N., Tahsili-Fahadan P., Riazi K., Ghahremani M.H., Dehpour A.R. Involvement of nitric oxide pathway in the acute anticonvulsant effect of melatonin in mice. Epilepsy Res 2006, 68:103-113.
32. Yahyavi-Firouz-Abadi N., Tahsili-Fahadan P., Riazi K., Ghahremani M.H., Dehpour A.R. Melatonin enhances the anticonvulsant and proconvulsant effects of morphine in mice: role for nitric oxide signaling pathway. Epilepsy Res 2007, 75:138-144.
33. Ray M., Mediratta P.K., Mahajan P., Sharma K.K. Evaluation of the role of melatonin in formalin-induced pain response in mice. Indian J Med Sci 2004, 58:122-130.
34. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
35. Samantaray S., Das A., Thakore N.P., et al. Therapeutic potential of melatonin in traumatic central nervous system injury. J Pineal Res 2009, 47:134-142.
36. Qiu W.W., Zheng R.Y. Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine. Neurosci Bull 2006, 22:187-191.
37. Arndt M.A., Battaglia V., Parisi E., et al. The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. Am J Physiol Cell Physiol 2009, 296:C1411-C1419.
38. Ismail S.A., Mowafi H.A. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 2009, 108:1146-1151.
39. Gong Z.H., Li Y.F., Zhao N., et al. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol 2006, 550:112-116.
40. Swinyard E.A., Kupferberg H.J. Antiepileptic drugs: detection, quantification, and evaluation. Fed Proc 1985, 44:2629-2633.
41. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
42. Gale K. Subcortical structures and pathways involved in convulsive seizure generation. J Clin Neurophysiol 1992, 9:264-277.
43. Kaputlu I., Uzbay T. L-NAME inhibits pentylenetetrazole and strychnine-induced seizures in mice. Brain Res 1997, 753:98-101.
44. Lapin I.P., Mirzaev S.M., Ryzov I.V., Oxenkrug G.F. Anticonvulsant activity of melatonin against seizures induced by quinolinate, kainate, glutamate, NMDA, and pentylenetetrazole in mice. J Pineal Res 1998, 24:215-218.
45. Munoz-Hoyos A., Sanchez-Forte M., Molina-Carballo A., et al. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J Child Neurol 1998, 13:501-509.
46. Dubocovich M.L. Melatonin receptors: are there multiple subtypes?. Trends Pharmacol Sci 1995, 16:50-56.
47. Morgan P.J., Barrett P., Howell H.E., Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994, 24:101-146.
48. Sugden D., Pickering H., Teh M.T., Garratt P.J. Melatonin receptor pharmacology: toward subtype specificity. Biol Cell 1997, 89:531-537.
49. Reiter R.J., Tan D.X., Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Ageing Dev 2002, 123:1007-1019.
50. Requintina P.J., Oxenkrug G.F. Effect of luzindole and other melatonin receptor antagonists on iron- and lipopolysaccharide-induced lipid peroxidation in vitro. Ann N Y Acad Sci 2007, 1122:289-294.
51. Fenoglio-Simeone K., Mazarati A., Sefidvash-Hockley S., et al. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav 2009, 16:52-57.
52. Stewart L.S., Leung L.S. Hippocampal melatonin receptors modulate seizure threshold. Epilepsia 2005, 46:473-480.
53. Derlet R.W., Albertson T.E. Acute cocaine toxicity: antagonism by agents interacting with adrenoceptors. Pharmacol Biochem Behav 1990, 36:225-231.
54. Horton R., Anlezark G., Meldrum B. Noradrenergic influences on sound-induced seizures. J Pharmacol Exp Ther 1980, 214:437-442.
55. Ashton D., Wauquier A. Alpha-noradrenaline modulation of D, L-allylgycine seizures. Eur J Pharmacol 1981, 75:71-74.
56. Reis D.J., Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 1998, 72:80-85.
57. Halaris A., Piletz J.E. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann N Y Acad Sci 2003, 1009:1-20.
58. Aricioglu F., Kan B., Yillar O., Korcegez E., Berkman K. Effect of agmatine on electrically and chemically induced seizures in mice. Ann N Y Acad Sci 2003, 1009:141-146.
59. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Rang and Dale's Pharmacology 2007, Elsevier. 6th ed.